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Purpose: The purpose of the present research was to the effect of camphor as a subliming agent on the 
mouth dissolving property of famotidine tablets.  
Method: Orodispersible tablets of famotidine were prepared using camphor as subliming agent and 
sodium starch glycollate together with crosscarmellose sodium as superdisintegrants. The formulations 
were evaluated for weight variation, hardness, friability, drug content, wetting time, in vitro and in-vivo 
dispersion, mouth feel and in vitro dissolution.  
Result: All the formulations showed low weight variation with dispersion time less than 30 seconds and 
rapid in vitro dissolution. The results revealed that the tablets containing subliming agent had a good 
dissolution profile. The drug content of all the formulations was within the acceptable limits of the United 
States Pharmacopoeia XXVII. The optimized formulation showed good release profile with maximum 
drug being released at all time intervals. 
Conclusion: This work helped in understanding the effect of formulation processing variables especially 
the subliming agent on the drug release profile. The present study demonstrated potentials for rapid 
absorption, improved bioavailability, effective therapy and patient compliance. 
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INTRODUCTION 
Tablet is the most widely used dosage form 
because of its convenience in terms of self-
administration, compactness and ease in 
manufacturing. Patients often experience 
difficulty in swallowing conventional tablets 
when water is not available nearby. 
Furthermore, paediatric and geriatric patients 
may also encounter inconvenience in 
swallowing it
1
. ‘Mouth dissolving’ (MD) or ‘melt 
in mouth’ tablets are a perfect fit for these 
patients as they immediately release the 
active drug, when placed on the tongue, by 
rapid disintegration, followed by dissolution of 
the drug
2,3,4
. Mouth dissolving tablets combine 
the advantage of both liquid and conventional 
tablet formulations allowing the ease of 
swallowing the drug in the form of liquid 
dosage form. Some drugs are absorbed from 
the mouth, pharynx and esophagus as the 
saliva passes down into the stomach. In such 
cases, the bioavailability of the drug is 
significantly increased over those observed in 
the conventional tablet dosage form. 
The basic approach to the development of 
mouth dissolving tablets is the use of 
superdisintegrants such as crosscarmellose 
sodium and sodium starch glycolate. Another 
approach used in developing MD tablets is 
maximizing the pore structure of the tablet 
matrix.  Freeze drying and vacuum drying 
techniques have been tried by researchers to 
maximize the pore structure of the tablet 
matrix. However, freeze drying is 
cumbersome and yields a fragile and 
hygroscopic product. Vacuum drying along 
with the sublimation of volatilizable ingredient 
has been employed to increase tablet 
porosity. While designing dispersible tablets, it 
is possible to achieve effective taste masking 
as well as a pleasant feel in the mouth. The 
main criterion for MD tablets is the ability to 
disintegrate or dissolve rapidly in saliva of the 
oral cavity in 15 to 60 seconds and have a 
pleasant mouth feel 
5
.  
Famotidine is a highly selective H2 receptor 
antagonist with properties of inhibiting gastric 
acid secretion and healing gastric & duodenal 
ulcers 
6
. Since the aqueous solubility of the 
drug is 0.1%w/v at 20°C
7
, it gives rise to 
difficulties in the formulation of dosage forms 
leading to variable dissolution rates 
8, 9
. In the 
present study, an attempt was made to 
develop mouth dissolving tablets of famotidine 
and to investigate the effect of subliming 
agent on the release profile of the drug in the 
tablets.  
 
MATERIALS AND METHODS 
Materials 
Famotidine was obtained as a gift from Tonira 
Pharmaceuticals, Ankhleshwar. sodium starch 
glycollate (SSG) and crosscarmellose sodium 
were also gifts from Recon Health Care Ltd, 
Bangalore. Camphor, sodium saccharin, 
mannitol, polyvinyl pyrollidone(PVP), talc and 
magnesium stearate were purchased from 
S.D. Fine Chemicals, Mumbai, India. 
 
Method 
Formulation of mouth dissolving tablets 
The orodispersible tablets of famotidine were 
prepared using the subliming agent, camphor, 
SSG and crosscarmellose sodium as 
superdisintegrants, mannitol as a diluent, 
sodium saccharin as sweetening agent, 
alcoholic solution of PVP (10%w/v) as binder 
and magnesium stearate with talc as a flow 
promoter (see Table 1). The drug and other 
ingredients were mixed together, and a 
sufficient quantity of alcoholic solution of PVP 
(10%w/v) was added and mixed to form a 
coherent mass. The wet mass was granulated 
using sieve no. 12 and regranulated after 
drying through sieve no. 16. Granules of the 
formulations containing either of the 
superdisintegrants but without camphor (F1 or 
F2) were dried in a tray dryer (Tempo 
instruments and equipments, Mumbai) at 
60
0
C for 30 min. resulting in localized drying. 
Since the melting point of famotidine is 163-
164 °C
7
, drying the granules at 60 
0
C  does 
not affect the stability of famotidine. Other 
granular formulations (F3 to F6) contained a 
subliming agent and were dried at room 
temperature, 20-22 
0
C for 8hrs. The final 
moisture content of the granules was found to 
be between 4-5%
10, 11
, which was determined 
using an IR moisture balance. The dried 
granules were then blended with talc, 
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magnesium stearate and compressed into 
tablets using a 8mm punch rotary tablet 
machine (Rimek, RSB-4 mini press Cadmach, 
Ahmedabad, India). Tablets from formulations 
 















Famotidine 20 20 20 20 20 20 
Sodium starch glycollate 
25 -- 25 -- 25 -- 
Crosscarmellose sodium 
-- 25 -- 25 -- 25 
Camphor 
-- -- 25 25 50 50 
Sodium saccharin 
2.5 2.5 2.5 2.5 2.5 2.5 
Mannitol 
195 195 170 170 145 145 
Magnesium stearate 
2.5 2.5 2.5 2.5 2.5 2.5 
Talc 




























F1 254 ± 3 97.4 4.3±1.2 0.457 48 65±2.1 
F2 255 ± 6 99.0 4.8±1.6 0.524 41 45±1.8 
F3 248 ± 7 94.5 4.3±2.1 0.635 20 28±1.4 
F4 249 ± 4 99.1 4.6±1.6 0.608 22 26±1.3 
F5 252 ± 2 96.3 3.8±1.4 0.968 17 24±1.7 
F6 253 ± 3 98.4 3.6±1.1 0.912 14 21±1.2 



























F1 F2 F3 F4 F5 F6
 
 
Fig. 1:  In vitro release profile of Famotidine formulations 
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F3 to F6 were further vacuum-dried at 60ºC 
until they reached constant weight. During 
drying, the camphor sublimed with the 
formation of a porous structure on the surface 
of the tablet.  
Evaluation of the tablets 
Hardness 
The crushing strength of the tablets was 
measured using a Monsanto hardness tester. 
Three tablets from each formulation batch 





Ten tablets were weighed and placed in a 
Roche friabilator and the equipment was 
rotated at 25 rpm for 4 min.  The tablets were 
taken out, dedusted and reweighed. The 
percentage friability of the tablets was 
measured as per the following formula, 
 
Percentage friability = 
Initial weight – Final weight   
x 100
 
                                    Initial weight 
Weight Variation 
Randomly, twenty tablets were selected after 
compression but before vacuum-drying (in the 
case of F3 to F6) and the mean weight was 
determined. . None of the tablets deviated 
from the average weight by more than ±7.5% 
(USP XX).  
Drug content 
Twenty tablets were weighed and powdered. 
An amount of the powder equivalent to 20mg 
of famotidine was dissolved in 100ml of pH 
6.8 phosphate buffer, filtered, diluted suitably 
and analyzed for drug content at 265nm using 





A piece of tissue paper (12cmx10.75cm) 
folded twice was placed in a Petri dish 
(Internal Diameter=9cm) containing 9ml of 
buffer solution simulating saliva pH 6.8, which  
had the following composition, NaCl (0.126g), 
KCl (0.964g), KSCN (0.189g), KH2PO4 
(0.655g) and urea (0.200g) in 1Litre of distilled 
water
14
. A tablet was placed on the paper and 
the time taken for complete wetting was 
noted. Three tablets from each formulation 
were randomly selected and the average 
wetting time was noted. The results are 
tabulated in Table 2.  
In vitro dispersion time
15 
In vitro dispersion time was measured by 
dropping a tablet in a 10ml measuring cylinder 
containing 6ml of buffer solution simulating 
saliva fluid (pH 6.8).  
Dissolution studies 
In vitro drug release studies of all the 
formulations were carried out using tablet 
dissolution test apparatus (USP TDT 06 PL, 
Electrolab, Mumbai) at 50rpm. Phosphate 
buffer pH6.8 was used as the dissolution 
media with temperature maintained at 
37±1ºC. Samples were withdrawn at different 
intervals, diluted suitably and analyzed at 
265nm for cumulative drug release using 
Shimadzu UV-Visible spectrophotometer. 
 
RESULTS  
Table 2 shows that all the formulated tablets 
exhibited low weight variation. Addition of a 
subliming agent had no pronounced effect on 
hardness and increased friability of the 
tablets. The wetting time, in vitro dispersion 
time of the tablets were also considerably 
reduced in tablets containing camphor (Table 
2). The drug content of all the formulations 
was found to be between 94.5 - 99.1% which 
was within the acceptable limits as per USP 
XXVII.  The in vitro dissolution profile (Fig.1) 
indicated faster and maximum drug release 
from formulation F4. 
 
DISCUSSION 
Tablets were prepared using 
superdisintegrants alone (F1 & F2) and in 
combination of a superdisintegrant and a 
subliming agent, camphor (F3 to F6). Addition 
of camphor in the formulation improved the 
tablet properties with respect to wetting time 
and in vitro dispersion time. Comparatively 
increased concentration of camphor in 
formulation F5 and F6 showed relatively 
decreased wetting time and in vitro dispersion 
time which may be attributed to faster uptake 
of water due to the porous structure formed 
thus facilitating the disintergrant to bring about 
faster disintegration. 
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CONCLUSION 
Overall, the results suggest that suitably 
formulated mouth-dissolving tablets of 
famotidine containing camphor as a subliming 
agent along with a super disintergrant 
(crosscarmellose sodium or sodium starch 
glycollate) can be achieved. The tablets 
exhibited good in vitro dispersion and wetting 
properties in presence of subliming agent. 
Thus the present study demonstrated 
potentials for rapid absorption, improved 
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